Register for OBR daily


To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

AVEO $1.25 0.3010 +31.72%
CVM $1.04 0.0840 +8.79%
PVCT $0.92 0.0410 +4.66%
PBYI $213.01 7.0500 +3.42%
FATE $4.98 0.1300 +2.68%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

CNDO $2.57 -0.2300 -8.21%
ADXS $9.00 -0.7300 -7.50%
BPTH $1.85 -0.1500 -7.50%
OMED $24.98 -1.7800 -6.65%
STML $15.19 -1.0100 -6.23%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 888 | 889 | 890 | 891 | 892 | 893 | 894 | 895 | 896 | 897 | Next > | Last >>

“Pure” Human Blood Stem-Cell Discovery Opens Door to Expanding Cells For More Clinical Use

(University Health Network, Toronto) July 7, 2011 - For the first time since stem cells were discovered here 50 years ago, scientists have isolated a human blood stem cell in its purest form – as a single stem cell capable of regenerating the entire blood system.
download pdf 

Cancer Patient Receives Lab-made Windpipe

(Los Angeles Times/AP) July 7, 2011 - A 36-year-old man who had tracheal cancer has received a new lab-made windpipe seeded with his own stem cells in a procedure in Sweden they call the first successful attempt of its kind, officials said Thursday.
read article (free registration required) 

How Bright Promise in Cancer Testing Fell Apart

(New York Times) July 7, 2011 - The Duke program — considered a breakthrough at the time — was the first fruit of the new genomics, a way of letting a cancer cell’s own genes reveal the cancer’s weaknesses. But the research at Duke turned out to be wrong.
read article 

Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients with Tuberous Sclerosis

(Novartis) July 8, 2011 - Novartis announced today Phase III trial results that showed more than one-third of patients taking Afinitor® (everolimus) tablets* experienced a 50% or greater reduction in the size of their subependymal giant cell astrocytomas (SEGAs), non-cancerous brain tumors associated with tuberous sclerosis complex (TSC).
read press release 

EU Clears Eli Lilly to Buy J&J Animal Health Unit

(Reuters) July 7, 2011 - U.S. drugmaker Eli Lilly & Co secured European Union regulatory approval on Thursday to buy Johnson & Johnson's animal health unit Janssen to boost its presence in Europe.
read article 

First Study of Its Kind Shows Benefits of Providing Medical Insurance to Poor

(New York Times) July 7, 2011 - When poor people are given medical insurance, they not only find regular doctors and see doctors more often but they also feel better, are less depressed and are better able to maintain financial stability, according to a new, large-scale study that provides the first rigorously controlled assessment of the impact of Medicaid.
read article 

Sanofi, Rib-X Sign Research Collaboration Deal on Antibiotics

(Fox Business/Dow Jones Newswires) July 6, 2011 - French pharmaceutical group Sanofi Wednesday said it signed an exclusive worldwide research collaboration agreement and option for license with U.S.-based Rib-X Pharmaceuticals, Inc. for novel classes of antibiotics resulting from Rib-X's RX-04 program for the treatment of resistant Gram-positive and resistant Gram-negative pathogens.
read article 

Pfizer Decides Against Radical Surgery

(Forbes/The Medicine Show blog) July 7, 2011 - Today Pfizer announced that it has come to a decision over what divisions it is going to try to spin off or sell and which ones it will keep. And some on Wall Street are likely to be disappointed.
read article 

Altos Solutions Announces Appointment of Carla C. Wood as President

(Altos) June 28, 2011 — Altos Solutions, Inc., the pioneer in web-based software applications for community-based oncology practices, announced today the appointment of Carla C. Wood, CPC, MS, as president.
read press release 

Robert "Bo" Gamble Joins Community Oncology Alliance as Director of Strategic Practice Initiatives

(Yahoo! Finance) June 6, 2011 - The Community Oncology Alliance (COA) announced today that Robert "Bo" Gamble has joined the organization as Director of Strategic Practice Initiatives.
read article 

Conquer Cancer Foundation of the American Society of Clinical Oncology Recognizes Leading Investigators For Work in Breast Cancer Research

(ASCO) July 7, 2011 - The Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO) today announced the 25 recipients of its 2011 Breast Cancer Symposium Merit Award, which recognizes researchers' contributions to progress against breast cancer.
read press release 

Southern U.S. States Lag in Reducing Death Rates From Colorectal Cancer

(AACR) July 7, 2011 - Improvements in colorectal cancer mortality rates are concentrated in the northern part of the United States, while southern states continue to fall behind, according to a report in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
read press release 

Will Outcry of Breast Cancer Patients Sway Federal Official?

(South Charlotte Weekly) July 7, 2011 - Shannon Morgan went to the nation’s capital to fight for her life.
read article 

Opinion: Extremely Expensive Cancer Drugs

(New York Times) July 6, 2011 - Many patients with advanced cancer must feel great relief after last week’s decisions by Medicare to pay for two drugs that provide limited medical benefits. For these patients, even a few more months of life is beyond price.
read article 

Wellstat Grants U.S. Distribution Rights to its Investigational Antidote for 5-FU Overexposure to Specialist Healthcare Company BTG

(Marketwatch) July 6, 2011 - Wellstat Therapeutics Corporation announced today that it has granted U.S. marketing rights for the company’s investigational drug uridine triacetate to the specialist healthcare company BTG International Inc. for use as a potential treatment for accidental overexposure to the chemotherapy drug fluorouracil (5-FU) due to dosing errors or impaired clearance of 5-FU from the body.
read article 

Idera Pharmaceuticals Provides Update on IMO-2055 Clinical Development Program

(Idera) July 7, 2011 - Idera Pharmaceuticals today provides an update on the clinical development of IMO-2055 (EMD 1201081), a TLR9 agonist for cancer treatment being developed by Merck KGaA, Darmstadt, Germany, under its collaboration with Idera.
read press release 

ZIOPHARM Oncology: Why This Tiny Biotech Has Attracted Fidelity and Other Big Investors

(Forbes blog) July 6 2011 - For a variety of reasons, one could say that ZIOPHARM Oncology, a tiny little-known biopharmaceutical company developing several anti-cancer drugs, is now several notches above its peers in the highly volatile and competitive biotech industry.
read article 

Phase 3 Trial of ZALTRAP (aflibercept) in Advanced Prostate Cancer to Continue as Planned at Recommendation of Independent Data Monitoring Committee

(Regeneron) July 7, 2011 - Regeneron Pharmaceuticals, Inc. today announced that the Phase 3 VENICE clinical trial evaluating the investigational agent ZALTRAP™ (aflibercept) in the first-line treatment of patients with androgen-independent (hormone-refractory) metastatic prostate cancer will continue to completion as planned.
read press release 

Previous Cancer History Increases Chances of Clotting Disorders After Knee Surgery, Study Suggests

(AOSSM) July 7, 2011 - A history of cancer was a significant risk factor for developing blood clotting issues following knee arthroscopy, according to a study being presented at the American Orthopaedic Society for Sports Medicine’s Annual Meeting in San Diego.
read press release 

'Detox Protein' is Collaborator in Pancreatic and Lung Cancer Development

(Cancer Research UK) July 6, 2011 – Cancer Research UK scientists have revealed that a ‘detox’ protein which mops up harmful ‘reactive oxygen’ in cells could also trigger pancreatic and lung cancer development, according to a study published in Nature, today.
read press release 

Experts Find Rogue Stem Cells in Liver Cancer

(Reuters) July 7, 2011 - Liver cancers are embedded with a type of super cancer stem cells that make them resistant to chemotherapy, spread to other body parts and stage a comeback even after they are surgically removed, researchers in Hong Kong reported on Thursday.
read article 

Half-Matched Transplants Widen Pool of Donors

(Johns Hopkins Medicine) July 6, 2011 - Identifying a suitable donor for leukemia and lymphoma patients who need bone marrow transplants may be far easier now that results of two clinical trials show transplant results with half-matched bone marrow or umbilical cord blood are comparable to fully matched tissue, thanks in large part to the availability of effective antirejection drugs and special post-transplant chemotherapy.
read press release 

TGen Presents Lung Cancer Studies at Amsterdam Conference

(Tgen) July 7, 2011 - The Translational Genomics Research Institute (TGen) is presenting two key studies, including one today, at the 14th World Conference on Lung Cancer, July 3-7 in Amsterdam.
read press release 

Synta Announces Presentation of Ganetespib Phase 2 Non-Small Cell Lung Cancer

(Synta) July 7, 2011 - Trial results at IASLC 14th World Conference on Lung Cancer: Ganetespib shows activity in crizotinib-refractory NSCLC patient; ganetespib and docetaxel combination shows activity in NSCLC.
read press release 

Cancer Patients With Blood Clots Gain No Benefit From Addition of a Vena Cava Filter to Treatment With Fondaparinux

(IASLC) July 7, 2011 - Cancer patients with blood clots -- which occur in one of every 200 cancer patients and are the second most common cause of death among cancer patients -- gain no benefit from the insertion of an inferior vena cava filter (IVCF) to the anticoagulant medication fondaparinux (Arixtra), according to research presented today at the 14th World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer.
read press release